| Jun-ki Park, MD | |
|
105 N Park Trl, Ste. 300, Stockbridge, GA 30281-7432 | |
| (678) 284-0800 | |
| (678) 284-9299 |
| Full Name | Jun-ki Park |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 19 Years |
| Location | 105 N Park Trl, Stockbridge, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861713471 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 25MA09080700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fresenius Medical Care Jonesboro, Llc | Jonesboro, GA | Dialysis facility |
| Rai Care Centers Of Stockbridge | Stockbridge, GA | Dialysis facility |
| Fresenius Medical Care Clayton County | Riverdale, GA | Dialysis facility |
| Piedmont Henry Hospital | Stockbridge, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Caritas Medical Center | 7012183478 | 4 |
News Archive
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
A new quantum sensor developed by researchers at the University of Waterloo's Institute for Quantum Computing
Washing hands with soap and water in preparation for delivery significantly reduced the risk of death for infants within the first month of life, according to a study in Nepal conducted by researchers at the Johns Hopkins Bloomberg School of Public Health.
Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).
How successful is the interdisciplinary treatment of breast cancer? Since 2003, the Breast Center at Heidelberg University Hospital has systematically tracked the course of breast cancer in more than 3,000 patients and, as the first center in Germany, has published these significant prospective results: Eighty-six percent of the patients survived the first five years after onset of treatment, with 80 % of them remaining disease-free during this period.
› Verified 4 days ago
| Entity Name | Caritas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245390681 PECOS PAC ID: 7012183478 Enrollment ID: O20120105000932 |
News Archive
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
A new quantum sensor developed by researchers at the University of Waterloo's Institute for Quantum Computing
Washing hands with soap and water in preparation for delivery significantly reduced the risk of death for infants within the first month of life, according to a study in Nepal conducted by researchers at the Johns Hopkins Bloomberg School of Public Health.
Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).
How successful is the interdisciplinary treatment of breast cancer? Since 2003, the Breast Center at Heidelberg University Hospital has systematically tracked the course of breast cancer in more than 3,000 patients and, as the first center in Germany, has published these significant prospective results: Eighty-six percent of the patients survived the first five years after onset of treatment, with 80 % of them remaining disease-free during this period.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jun-ki Park, MD 105 N Park Trl, Ste. 300, Stockbridge, GA 30281-7432 Ph: (678) 284-0200 | Jun-ki Park, MD 105 N Park Trl, Ste. 300, Stockbridge, GA 30281-7432 Ph: (678) 284-0800 |
News Archive
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
A new quantum sensor developed by researchers at the University of Waterloo's Institute for Quantum Computing
Washing hands with soap and water in preparation for delivery significantly reduced the risk of death for infants within the first month of life, according to a study in Nepal conducted by researchers at the Johns Hopkins Bloomberg School of Public Health.
Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).
How successful is the interdisciplinary treatment of breast cancer? Since 2003, the Breast Center at Heidelberg University Hospital has systematically tracked the course of breast cancer in more than 3,000 patients and, as the first center in Germany, has published these significant prospective results: Eighty-six percent of the patients survived the first five years after onset of treatment, with 80 % of them remaining disease-free during this period.
› Verified 4 days ago
Dr. Ashar Ul Islam Usmani, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 135 N Park Pl, Stockbridge, GA 30281 Phone: 770-505-1500 | |
Deepa Nankani, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 404-367-3014 | |
Gurinderjit Kaur Sidhu, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1050 Eagles Landing Pkwy Ste 302, Stockbridge, GA 30281 Phone: 770-507-0070 Fax: 770-507-7463 | |
Nizar Ali Tejani, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1004 Hospital Drive, Stockbridge, GA 30281 Phone: 770-507-9929 Fax: 770-507-9930 | |
Dr. Saurabh Singh, M.D Nephrology Medicare: May Accept Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 404-367-3014 | |
Dhruv Chawla, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 350 Country Club Dr Ste A, Stockbridge, GA 30281 Phone: 770-692-4000 | |
Dr. Kyoo Ricard, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3579 Highway 138 Se, Suite 101, Stockbridge, GA 30281 Phone: 770-507-0029 Fax: 770-507-9990 |